| Coumarins: old compounds with novel promising therapeutic perspectives ME Riveiro, N De Kimpe, A Moglioni, R Vazquez, F Monczor, C Shayo, ... Current medicinal chemistry 17 (13), 1325-1338, 2010 | 509 | 2010 |
| The BET bromodomain inhibitor OTX015 affects pathogenetic pathways in preclinical B-cell tumor models and synergizes with targeted drugs M Boi, E Gaudio, P Bonetti, I Kwee, E Bernasconi, C Tarantelli, A Rinaldi, ... Clinical Cancer Research 21 (7), 1628-1638, 2015 | 312 | 2015 |
| BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells MM Coudé, T Braun, J Berrou, M Dupont, S Bertrand, A Masse, E Raffoux, ... Oncotarget 6 (19), 17698, 2015 | 264 | 2015 |
| Unraveling galectin-1 as a novel therapeutic target for cancer L Astorgues-Xerri, ME Riveiro, A Tijeras-Raballand, M Serova, C Neuzillet, ... Cancer treatment reviews 40 (2), 307-319, 2014 | 248 | 2014 |
| Structural insights into hydroxycoumarin-induced apoptosis in U-937 cells ME Riveiro, A Moglioni, R Vazquez, N Gomez, G Facorro, L Piehl, ... Bioorganic & medicinal chemistry 16 (5), 2665-2675, 2008 | 200 | 2008 |
| Targeting MYCN-driven transcription by BET-bromodomain inhibition A Henssen, K Althoff, A Odersky, A Beckers, R Koche, F Speleman, ... Clinical Cancer Research 22 (10), 2470-2481, 2016 | 181 | 2016 |
| OTX015 (MK‐8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma … C Berenguer‐Daizé, L Astorgues‐Xerri, E Odore, M Cayol, E Cvitkovic, ... International journal of cancer 139 (9), 2047-2055, 2016 | 131 | 2016 |
| OTX008, a selective small-molecule inhibitor of galectin-1, downregulates cancer cell proliferation, invasion and tumour angiogenesis L Astorgues-Xerri, ME Riveiro, A Tijeras-Raballand, M Serova, ... European journal of cancer 50 (14), 2463-2477, 2014 | 125 | 2014 |
| Insights on the CXCL12-CXCR4 axis in hepatocellular carcinoma carcinogenesis I Ghanem, ME Riveiro, V Paradis, S Faivre, PMV de Parga, E Raymond American journal of translational research 6 (4), 340, 2014 | 101 | 2014 |
| Phase I population pharmacokinetic assessment of the oral bromodomain inhibitor OTX015 in patients with haematologic malignancies E Odore, F Lokiec, E Cvitkovic, M Bekradda, P Herait, F Bourdel, C Kahatt, ... Clinical pharmacokinetics 55, 397-405, 2016 | 99 | 2016 |
| The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus R Vázquez, ME Riveiro, L Astorgues-Xerri, E Odore, K Rezai, E Erba, ... Oncotarget 8 (5), 7598, 2017 | 88 | 2017 |
| Epigenetic control of mitochondrial fission enables self-renewal of stem-like tumor cells in human prostate cancer G Civenni, R Bosotti, A Timpanaro, R Vazquez, J Merulla, S Pandit, ... Cell metabolism 30 (2), 303-318. e6, 2019 | 73 | 2019 |
| Focus on the role of the CXCL12/CXCR4 chemokine axis in head and neck squamous cell carcinoma S Albert, ME Riveiro, C Halimi, M Hourseau, A Couvelard, M Serova, ... Head & neck 35 (12), 1819-1828, 2013 | 59 | 2013 |
| Toddaculin, a natural coumarin from Toddalia asiatica, induces differentiation and apoptosis in U-937 leukemic cells R Vázquez, ME Riveiro, M Vermeulen, C Mondillo, PH Coombes, ... Phytomedicine 19 (8-9), 737-746, 2012 | 59 | 2012 |
| Tiotidine, a Histamine H2 Receptor Inverse Agonist That Binds with High Affinity to an Inactive G-Protein—Coupled Form of the Receptor. Experimental Support for the Cubic … F Monczor, N Fernandez, BL Legnazzi, ME Riveiro, A Baldi, C Shayo, ... Molecular pharmacology 64 (2), 512-520, 2003 | 58 | 2003 |
| OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations ME Riveiro, L Astorgues-Xerri, R Vazquez, R Frapolli, I Kwee, A Rinaldi, ... Oncotarget 7 (51), 84675, 2016 | 56 | 2016 |
| Biochemical mechanisms underlying the pro-apoptotic activity of 7, 8-dihydroxy-4-methylcoumarin in human leukemic cells ME Riveiro, R Vazquez, A Moglioni, N Gomez, A Baldi, C Davio, C Shayo Biochemical pharmacology 75 (3), 725-736, 2008 | 56 | 2008 |
| Induction of cell differentiation in human leukemia U-937 cells by 5-oxygenated-6, 7-methylenedioxycoumarins from Pterocaulon polystachyum ME Riveiro, C Shayo, F Monczor, N Fernández, A Baldi, N De Kimpe, ... Cancer letters 210 (2), 179-188, 2004 | 55 | 2004 |
| Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib M Serova, A de Gramont, A Tijeras-Raballand, C Dos Santos, ME Riveiro, ... Cancer chemotherapy and pharmacology 71, 1297-1307, 2013 | 52 | 2013 |
| Toward establishing structure–activity relationships for oxygenated coumarins as differentiation inducers of promonocytic leukemic cells ME Riveiro, D Maes, R Vázquez, M Vermeulen, S Mangelinckx, J Jacobs, ... Bioorganic & medicinal chemistry 17 (18), 6547-6559, 2009 | 52 | 2009 |
